Anil Suryabanshi1, Binita Timilsina2, Namrata Khadka3, Ashes Rijal2, Ramesh Singh Bhandari3. 1. Maharajgunj Medical Campus, Institute of Medicine, 44600 Kathmandu, Nepal. Electronic address: anilsuryabanshi1462@gmail.com. 2. Maharajgunj Medical Campus, Institute of Medicine, 44600 Kathmandu, Nepal. 3. Department of Gastrointestinal and General Surgery, Tribhuvan University Teaching Hospital, Institute of Medicine, 44600, Nepal.
Abstract
INTRODUCTION AND IMPORTANCE: Retroperitoneal liposarcoma is a rare entity originating from adipocytes. Before showing any symptoms, it can grow hugely and envelop nearby structures. Surgery is the optimum course of treatment, however, well-differentiated liposarcomas make it challenging to discern between malignant and normal adipocytes during surgery. CASE PRESENTATION: We report a case of a 62-year-old male referred to evaluate his abdominal distention presented for four years. Recently he had developed loin pain for six months. A computerized tomography scan showed extensive tumor encompassing the right kidney and ureter, colon, and duodenum, however, exploratory laparotomy revealed free colon and duodenum. Complete resection of the mass with a right nephrectomy was performed. Subsequently, a histopathological assessment of the resected specimen confirmed the diagnosis of well-differentiated liposarcoma. Adjuvant chemotherapy was initiated as the tumor was a high-risk sarcoma but local recurrence was observed after 2 years despite surgery and chemotherapy. CLINICAL DISCUSSION: Imaging modalities are the mainstay of preoperative diagnosis. Preferably, surgical resection with a tumor-free margin is recommended to avoid tumor recurrence which remains the primary challenge. This, along with the grade of the tumor, multifocal disease, and invasion of adjacent structure dictate the prognosis of the disease. Adjuvant chemotherapy and radiotherapy are not regarded as standard therapies for resectable retroperitoneal liposarcoma, although further research is still needed to determine their value in the case of high-risk sarcoma. CONCLUSION: Retroperitoneal liposarcoma has the potential to present as huge asymptomatic masses which with an added predilection for recurrence poses a huge challenge to any surgeon.
INTRODUCTION AND IMPORTANCE: Retroperitoneal liposarcoma is a rare entity originating from adipocytes. Before showing any symptoms, it can grow hugely and envelop nearby structures. Surgery is the optimum course of treatment, however, well-differentiated liposarcomas make it challenging to discern between malignant and normal adipocytes during surgery. CASE PRESENTATION: We report a case of a 62-year-old male referred to evaluate his abdominal distention presented for four years. Recently he had developed loin pain for six months. A computerized tomography scan showed extensive tumor encompassing the right kidney and ureter, colon, and duodenum, however, exploratory laparotomy revealed free colon and duodenum. Complete resection of the mass with a right nephrectomy was performed. Subsequently, a histopathological assessment of the resected specimen confirmed the diagnosis of well-differentiated liposarcoma. Adjuvant chemotherapy was initiated as the tumor was a high-risk sarcoma but local recurrence was observed after 2 years despite surgery and chemotherapy. CLINICAL DISCUSSION: Imaging modalities are the mainstay of preoperative diagnosis. Preferably, surgical resection with a tumor-free margin is recommended to avoid tumor recurrence which remains the primary challenge. This, along with the grade of the tumor, multifocal disease, and invasion of adjacent structure dictate the prognosis of the disease. Adjuvant chemotherapy and radiotherapy are not regarded as standard therapies for resectable retroperitoneal liposarcoma, although further research is still needed to determine their value in the case of high-risk sarcoma. CONCLUSION: Retroperitoneal liposarcoma has the potential to present as huge asymptomatic masses which with an added predilection for recurrence poses a huge challenge to any surgeon.
Authors: W O Russell; J Cohen; F Enzinger; S I Hajdu; H Heise; R G Martin; W Meissner; W T Miller; R L Schmitz; H D Suit Journal: Cancer Date: 1977-10 Impact factor: 6.860
Authors: Sylvie Bonvalot; Alessandro Gronchi; Cécile Le Péchoux; Carol J Swallow; Dirk Strauss; Pierre Meeus; Frits van Coevorden; Stephan Stoldt; Eberhard Stoeckle; Piotr Rutkowski; Marco Rastrelli; Chandrajit P Raut; Daphne Hompes; Antonino De Paoli; Claudia Sangalli; Charles Honoré; Peter Chung; Aisha Miah; Jean Yves Blay; Marco Fiore; Jean-Jacques Stelmes; Angelo P Dei Tos; Elizabeth H Baldini; Saskia Litière; Sandrine Marreaud; Hans Gelderblom; Rick L Haas Journal: Lancet Oncol Date: 2020-09-14 Impact factor: 41.316
Authors: Penella J Woll; Peter Reichardt; Axel Le Cesne; Sylvie Bonvalot; Alberto Azzarelli; Harald J Hoekstra; Michael Leahy; Frits Van Coevorden; Jaap Verweij; Pancras C W Hogendoorn; Monia Ouali; Sandrine Marreaud; Vivien H C Bramwell; Peter Hohenberger Journal: Lancet Oncol Date: 2012-09-04 Impact factor: 41.316